Se connecter

Bibliographies thématiques / Immunogeni / Livres

Livres sur le sujet « Immunogeni »

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Immunogeni.

Auteur : Grafiati

Publié le 11 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 25 meilleurs livres pour votre recherche sur le sujet « Immunogeni ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les livres sur diverses disciplines et organisez correctement votre bibliographie.

1

Koprowski, Hilary, et Fritz Melchers, dir. Peptides as Immunogens. Berlin, Heidelberg : Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71440-5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Lawson, David Alexander. Identification of immunogenic proteins of litomosoides carinii (Nematoda, Filarioidea). Salford : University of Salford, 1988.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Peptides as Immunogens. Berlin : Springer-Verlag, 1986.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Melchers, Fritz, et Hilary Koprowski. Peptides As Immunogens. Springer London, Limited, 2012.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Melchers, Fritz, et Hilary Koprowski. Peptides As Immunogens. Springer, 2011.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Kitazawa, Haruki, Susana Alvarez et Julio Villena. Probiotics : Immunobiotics and Immunogenics. Taylor & Francis Group, 2013.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Kitazawa, Haruki, Susana Alvarez et Julio Villena. Probiotics : Immunobiotics and Immunogenics. Taylor & Francis Group, 2013.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Probiotics immunobiotics and immunogenics. CRC Press, 2014.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Bruce, Simon. Probiotics : Immunobiotics and Immunogenics. Murphy & Moore Publishing, 2022.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Kitazawa, Haruki. Probiotics : Immunobiotics and Immunogenics. Taylor & Francis Group, 2013.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

Koprowski, H. Peptides As Immunogens (Current Topics in Microbiology and Immunology). Springer, 1986.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

Agin, Tonia S. Immunogenic potential of temperature-sensitive mutants of Escherichia coli. 1994.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

13

Garg, Abhishek D., et Patrizia Agostinis, dir. Immunogenic Cell Death in Cancer : From Benchside Research to Bedside Reality. Frontiers Media SA, 2016. http://dx.doi.org/10.3389/978-2-88919-838-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

Cai, Ann. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. 2012.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

15

Ruud, Even. Toward a Sociology of Music Therapy : Musicking As a Cultural Immunogen. Barcelona Publishers, 2020.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

16

Ltd, ICON Group. IMMUNOGEN, INC. : International Competitive Benchmarks and Financial Gap Analysis (Financial Performance Series). 2^e éd. Icon Group International, 2000.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

17

Ltd, ICON Group. IMMUNOGEN, INC. : Labor Productivity Benchmarks and International Gap Analysis (Labor Productivity Series). 2^e éd. Icon Group International, 2000.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

18

Petrov, R. V. Immunology : Cell Interactions, Myelopeptides Artificial Immunogens (Soviet Medical Reviews Section D, Immunology Reviews, Vol 1). Routledge, 1987.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

19

Protocol to evaluate the safety and efficacy of immunogens against bovine anaplasmosis and babesiasis [i.e., babesiosis]. Santiago, Chile : FAO Regional Office for Latin America and the Caribbean, 1995.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Petrov, R. V. Physico-Chemical Criteria for the Construction of Artificial Immunomodulators and Immunogens on the Basis of Polyelectrolyte Complexes. Routledge, 1992.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Kloning ekspresi dan karakterisasi protein domain immunogenik pfsera isolat Indonesia : Suatu calon subunit vaksin malaria khas Indonesia. Surabaya : Lembaga Penelitian dan Pengabdian Kepada Masyarakat, Universitas Airlangga, 2007.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Lavoué, Vincent, Patrick Legembre, Jean Levêque, Fabrice Foucher, Sébastien Henno et Florian Cabillic. Ovarian Cancer Immunity. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0003.

Texte intégral

Résumé :

Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women, and there has been no substantial decrease in the death rates due to EOC in the past three decades. Thus, basic knowledge regarding ovarian tumor cell biology is urgently needed to allow the development of innovative treatments for EOC. Traditionally, EOC has not been considered an immunogenic tumor, but there is evidence of an immune response to EOC in patients. Clinical data demonstrate that an anti-tumor immune response and immune evasion mechanisms are correlated with a better and lower survival, respectively, providing evidence for the immunoediting hypothesis in EOC. This chapter focuses on the immune response and immune suppression in EOC.

Styles APA, Harvard, Vancouver, ISO, etc.

23

Stein, Matthew A. Lymphadenopathy. Sous la direction de Christoph I. Lee, Constance D. Lehman et Lawrence W. Bassett. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190270261.003.0051.

Texte intégral

Résumé :

Lymphadenopathy is a pathological or abnormal state of one or more lymph nodes in a nodal basin that occurs in response to pathogens, immunogens, or malignant cells that are detected within the lymph. Malignant lymphadenopathy may be detected by physical exam and/or imaging findings, but it is ultimately confirmed or excluded by histological evaluation. This chapter, appearing in the section on nipple, skin, and lymph nodes, reviews key imaging and clinical features, imaging protocols and pitfalls, differential diagnoses, and management recommendations of lymphadenopathy detected by mammography, tomosynthesis, and ultrasound (US). Topics include the anatomy and physiology of breast lymphatic function, the anatomy and imaging features of lymph nodes, differential diagnosis of lymphadenopathy, and the imaging assessment of the axillary nodal basin in the context of known breast cancer.

Styles APA, Harvard, Vancouver, ISO, etc.

24

Drerup, Justin M., Curtis A. Clark et Tyler J. Curiel. Clinical Trials of Ovarian Cancer Immunotherapy and Future Directions. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0013.

Texte intégral

Résumé :

Ovarian cancer (OC) is an immunogenic tumor and among the first where measures of anti-tumor immunity correlated with improved survival. Thus, immunotherapy could be a viable OC treatment modality. Nonetheless, clinical OC immunotherapy trials have demonstrated only modest successes at best, and there is currently no Food and Drug Administration (FDA)approved OC immune therapy despite recent successes in other carcinomas and lymphomas and FDA-approved immunotherapy agents for them. New data suggest specific impediments to effective de novo and treatment-induced anti-OC immunity and support the concept that effective, tolerable OC immunotherapy could be developed based on these newer insights. This chapter reviews the history of OC immunotherapy, highlights important discoveries in OC-related immune dysfunction, covers promising recent developments, highlights newer and ongoing clinical trials, and speculates on future directions that could lead to improved OC immunotherapy approaches.

Styles APA, Harvard, Vancouver, ISO, etc.

25

Vaheri, Antti, James N. Mills, Christina F. Spiropoulou et Brian Hjelle. Hantaviruses. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198570028.003.0035.

Texte intégral

Résumé :

Hantaviruses (genus Hantavirus, family Bunyaviridae) are rodent- and insectivore-borne zoonotic viruses. Several hantaviruses are human pathogens, some with 10-35% mortality, and cause two diseases: hemorrhagic fever with renal syndrome (HFRS) in Eurasia, and hantavirus cardiopulmonary syndrome (HCPS) in the Americas. Hantaviruses are enveloped and have a three-segmented, single-stranded, negative-sense RNA genome. The L gene encodes an RNA-dependent RNA polymerase, the M gene encodes two glycoproteins (Gn and Gc), and the S gene encodes a nucleocapsid protein. In addition, the S genes of some hantaviruses have an NSs open reading frame that can act as an interferon antagonist. Similarities between phylogenies have suggested ancient codivergence of the viruses and their hosts to many authors, but increasing evidence for frequent, recent host switching and local adaptation has led to questioning of this model. Infected rodents establish persistent infections with little or no effect on the host. Humans are infected from aerosols of rodent excreta, direct contact of broken skin or mucous membranes with infectious virus, or rodent bite. One hantavirus, Andes virus, is unique in that it is known to be transmitted from person-to-person. HFRS and HCPS, although primarily affecting kidneys and lungs, respectively, share a number of clinical features, such as capillary leakage, TNF-, and thrombocytopenia; notably, hemorrhages and alterations in renal function also occur in HCPS and cardiac and pulmonary involvement are not rare in HFRS. Of the four structural proteins, both in humoral and cellular immunity, the nucleocapsid protein appears to be the principal immunogen. Cytotoxic T-lymphocyte responses are seen in both HFRS and HCPS and may be important for both protective immunity and pathogenesis. Diagnosis is mainly based on detection of IgM antibodies although viral RNA (vRNA) may be readily, although not invariably, detected in blood, urine and saliva. For sero/genotyping neutralization tests/RNA sequencing are required. Formalin-inactivated vaccines have been widely used in China and Korea but not outside Asia. Hantaviruses are prime examples of emerging and re-emerging infections and, given the limited number of rodents and insectivores thus far studied, it is likely that many new hantaviruses will be detected in the near future.

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!